The JointJYNT -7.49%64 EBITDA Margin % is 8.79% as of Mar. 2026, which is 25% above its 10-year median of 7.03. GuruFocus rates JYNT with a GF Score™ of 64/100 and a GF Value™ of $11.11 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, The Joint ranks worse than 66.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. The Joint's EBITDA for the
three
months ended in Mar. 2026 was $1.30 Mil. The Joint's Revenue for the
three
months ended in Mar. 2026 was $14.82 Mil. Therefore, The Joint's EBITDA margin for the quarter that ended in Mar. 2026 was 8.79%.
The Joint (NAS:JYNT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
The Joint EBITDA Margin % Related Terms
The Joint EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for The Joint's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JYNT vs MAHN, WW, PARK: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, The Joint's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Joint EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Joint's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where The Joint's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Joint (JYNT) has a EBITDA Margin % of 8.79% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on The Joint and its competitors. This is 25% above median its historical median of 7.03. According to the industry distribution chart, The Joint ranks #442 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 66.2%.
Is The Joint's EBITDA Margin % too high?
The Joint's current EBITDA Margin % of 8.79% is 25% above median its 10-year median of 7.03. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. The Joint's value of 8.79% is 13.9% below this industry median. Based on the distribution chart, The Joint ranks #442 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, The Joint has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Joint's EBITDA Margin % compare to MAHN and WW?
According to the Healthcare Providers & Services industry distribution chart, The Joint ranks #442 out of 668 companies for EBITDA Margin %. This places The Joint in the lower half of its industry. The industry median EBITDA Margin % is 10.21. The Joint's value of 8.79% is 13.9% below this benchmark. While the company's 10-year median is 7.03 vs. the industry median of 10.21, The Joint has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Joint's current EBITDA Margin % of 8.79% is 13.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on The Joint and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Joint's current EBITDA Margin % is 8.79%, which is 25% above median its own 10-year median of 7.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Joint stock overvalued right now?
Based on GuruFocus' analysis, The Joint (JYNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.11, compared to a current price of $8.52 — trading 23.3% below its estimated fair value. The current EBITDA Margin % is 8.79%, which is 25% above median its 10-year median of 7.03 and 13.9% below the Healthcare Providers & Services industry median of 10.21. The Joint's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For The Joint (JYNT), the current EBITDA Margin % is 8.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Joint (JYNT) Overvalued in 2026?
Based on GuruFocus' analysis, The Joint stock appears to be undervalued.
The current stock price of $8.52 is trading 23.3% below its estimated GF Value™ of $11.11.
GuruFocus considers The Joint to be Modestly Undervalued.
Key valuation signals for JYNT:
EBITDA Margin %: 8.79% (25% above median its 10-year median of 7.03)
GF Value™: $11.11 vs. price of $8.52 (23.3% below fair value)
Industry Position: 13.9% below the Healthcare Providers & Services median (#442 of 668)
No single metric tells the full story. See the JYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
64GF Score
Get the complete analysis for JYNT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JYNT has been successfully added to your 
